1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Advagene Biopharma Co., Ltd.

Advagene Biopharma Co., Ltd.

TTPEX:6709
24.00
TWD
+0.40
(+1.69%)
1.70BMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-3.98
-4.66
-3.09
-2.04
-1.56
-1.88
-2.39
-1.72
-1.26
-1.14
- -
Free Cash Flow per Basic Share
-6.4
-6.27
-1.1
-0.93
-0.7
-1.37
-2.41
-1.45
-1.29
-1.1
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3.13
4.74
7.7
5.98
6.63
4.99
2.63
2.61
3.7
2.55
5.14
Tangible Book Value per Share
2.81
4.3
7.34
5.57
6.32
4.81
2.44
2.61
3.7
2.55
5.02
Basic Weighted Avg Shares
23
30
36
45
45
49
50
54
55
60
60
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
3
4
5
7
8
8
12
12
2
2
- -
Net Income, GAAP
-91
-138
-111
-92
-70
-93
-118
-92
-69
-68
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
120
188
326
249
282
236
117
138
218
147
344
LT Debt
- -
- -
- -
- -
4
3
1
- -
5
3
2
Total Equity
141
214
347
271
299
250
132
140
221
152
356
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-77.89
-39.71
-29.64
-24.59
-33.77
-62.09
-67.8
-38.51
-36.64
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
2
3
2
LT Borrowings
- -
- -
- -
LT Finance Leases
4
3
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
60
60
69
Market Capitalization
1,256
1,666
1,703

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
191
159
351
Cash, Cash Equivalents & STI
168
135
325
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
12
8
Payables & Accruals
- -
- -
- -
ST Debt
2
3
2
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-6.2%
-30.96%
Free Cash Flow
- -
28.05%
-7.71%
Net Income, GAAP
- -
2.27%
-1.63%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-1.26
2025
- -
- -
-1.14
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yu Shen Hsu
Full Time Employees
16
Sector
Health technology
Industry
Biotechnology
Address
No. 308, Neihu Road Taipei TP Taiwan 114
IPO Date
Nov 29, 2018
Website
advagene.com.tw
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Advagene Biopharma Co., Ltd. (6709.TWO) develops and manufactures gene therapy vectors and related biopharmaceutical products for treating genetic and chronic diseases. The company offers adeno-associated virus (AAV) vectors, including AAV2, AAV5, AAV8, and AAV9 serotypes customized for specific therapeutic applications; plasmid DNA production services; and viral vector packaging platforms for research, preclinical, and clinical use. Its product portfolio encompasses GMP-grade viral vectors, helper plasmids, and cell lines such as HEK293 for gene delivery systems targeting ophthalmology, neurology, and oncology indications. Advagene operates primarily in Taiwan and Asia-Pacific markets, serving pharmaceutical companies, contract development and manufacturing organizations (CDMOs), and academic institutions. Founded in 2016 and headquartered in Taipei, Taiwan, the company recently expanded its production capacity through a new GMP facility in 2024 to meet growing demand for high-titer AAV vectors; formed a strategic manufacturing partnership with a leading U.S. biotech firm in early 2025 for co-development of retinal disease therapies; and launched an enhanced AAV9-based platform for central nervous system disorders following successful preclinical data reported in late 2024. No subsidiaries or parent entities are reported.